Dermata Therapeutics(DRMA) - 2023 Q4 - Annual Results

EX-99.1 2 drma_ex991.htm PRESS RELEASE Anticipated Upcoming Milestones - Initiated enrollment of DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial in Q4 2023 - 1 - Raised $9.1 million in gross proceeds from three financings completed in 2023 - - Received issuance of Japanese patent for DMT410 for the treatment of hyperhidrosis - SAN DIEGO, CA, March 21, 2024 – Dermata Therapeutics, Inc. (Nasdaq: DRMA; DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused ...